Stockreport

Takeda Pharmaceutical Showcases Strong Phase III Psoriasis Data for Zasocitinib, Eyes 2027 Launch [Yahoo! Finance]

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)  (TAK) 
PDF Takeda Pharmaceutical (NYSE:TAK) highlighted late-breaking Phase III data for investigational TYK2 inhibitor zasocitinib in moderate-to-severe plaque psoriasis and outl [Read more]